Aktuellt
SENASTE
Redeye comments on the news that the company’s complementary clinical study TRIAC II, which focused on neurocognition in young MTC8 patients, did not achieve its co-primary endpoints. However, it did replicate findings needed for regulatory approvals. We give our initial comment.
LÄS MER
